Pharmacologic suppression of target cell recognition by engineered T cells expressing chimeric T-cell receptors

Cancer Gene Therapy

Volumn 7, Issue 4, 2000, Pages 526-529

  Álvarez Vallina, Luis ^a   Yañez, Rosa ^a   Blanco, Bélen ^a   Gil, Magdalena ^a   Russell, Stephen J ^b  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b MAYO CLINIC   (United States)

Author keywords

Chimeric T cell receptors; Engineered T cells; Tetracycline suppressible promoter

Indexed keywords

T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; EFFECTOR CELL; GENE REPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; T LYMPHOCYTE; TARGET CELL;

ANIMALIA;

EID: 0343091364     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700128     Document Type: Article

References (16)

1. Abken H, Hombach A, Reinhold U, Ferrone S. Can combined T-cell- and antibody-based immunotherapy out-smart tumor cells? Immunol Today. 1998;19:2-5.
2. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulins and T-cell receptors. Proc Natl Acad Sci USA. 1993;90:720-724.
3. Hwu P, Shafer GE, Treisman J, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor γ chain. J Exp Med. 1993;178:361-366.
4. Hwu P, Yang JC, Cowherd, R, et al. In vitro antitumor activity of T cells redirected with chimeric antibody T-cell receptor genes. Cancer Res. 1995;55:3369-3373.
5. Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z. Targeting of lymphocytes to Neu/HER2-expressing cells using chimeric single-chain Fv receptors. J Immunol. 1993;151:6577-6582.
6. Moritz D, Wels W, Mattern J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA. 1994;91:4318-4322.
7. Altenschmidt U, Klundt E, Groner B. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression. J Immunol. 1997;159:5509-5515.
8. Pardoll D. Cancer. Curr Opin Immunol. 1994;6:705-706.
9. Hege KM, Cooke KS, Finer MH, Zsebo KM, Roberts MR. Systemic T cell-independent tumor immunity after transplantation of universal receptor-modified bone marrow into SCID mice. J Exp Med. 1996;184:2261-2269.
10. Alvarez-Vallina L, Agha-Mohammadi S, Hawkins RE, Russell SJ. Pharmacological control of antigen responsiveness in genetically modified T lymphocytes. J Immunol. 1997;159:5889-5895.
11. Gossen M, Budjard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA. 1992;89:5547-5551.
12. Alvarez-Vallina L, Hawkins RE. Antigen-specific targeting of CD28-mediated T-cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur J Immunol. 1996;26:2304-2309.
13. Hawkins RE, Russell SJ, Winter G. Selection of phage antibodies by binding affinity: mimicking affinity maturation. J Mol Biol. 1992;226:889-896.
14. Boehme SA, Lenardo MJ. Ligand-induced apoptosis of mature T lymphocytes (propriocidal regulation) occurs at distinct stages of the cell cycle. Leukemia. 1993;7:845-849.
15. Vukmanovic S. The molecular jury: deciding whether immature thymocytes should live or die. J Exp Med. 1996;184:305-309.
16. Jameson SC, Hogquist KA, Bevan MJ. Positive selection of thymocytes. Annu Rev Immunol. 1995;13:93-126.